Revised July 2012
Division of Basic Neuroscience & Behavior Research (DBNBR)
| Name | Interests |
|---|---|
| Beth Babecki | Institutional, individual and career development training grants. |
| Mark Caulder | Human genetics of drug dependence and addiction, candidate gene expression, next generation sequencing, genome-wide association studies. |
| Christine Colvis, Ph.D. | Proteomics, technology development, neuroscience and co-morbid conditions such as HIV and hepatitis C. |
| Jonathan D. Pollock, Ph.D. | Molecular genetics of substance abuse, molecular genetics of synaptic plasticity and memory, model organisms. |
| Joni L. Rutter, Ph.D. | Human and population genetics, pharmacogenetics, gene x gene, gene x environment interactions, molecular genetics of drug addiction and addiction vulnerability, and ELSI issues. |
| John Satterlee, Ph.D. | Model organisms and behavioral genetics, RNAi and microRNAs, epigenetics, signal transduction. |
| Karen Skinner, Ph.D. | Systems biology, data integration, multilevel modeling, biomedical computation. |
| Susan Volman, Ph.D. | Behavioral genetics of drug abuse and of co-occuring disorders in animal models. |
| Da-yu Wu, Ph.D. | Neural development, molecular genetics, animal models, and RNAi. |
Division of Clinical Neuroscience, Development and Behavioral Research (DCNBR)
| Name | Interests |
|---|---|
| Harold Gordon, Ph.D. | Human genetics of drug abuse vulnerability and resilience, risks associated with early or chronic stress, interactions between drug use and sleep disturbances/circadian rhythms. |
| Steven Grant | Brain imaging and radiotracer development, cognitive neuroscience, decision-making. |
| Karen Sirocco, Ph.D. | Gene by environment by development interactions that impact neurobehavior, cognition, and drug use resilience or vulnerability. |
Division of Epidemiology, Services, and Prevention Research (DESPR)
| Name | Interests |
|---|---|
| Kevin P. Conway, Ph.D. | Familial and genetic vulnerability, phenotypic heterogeneity of drug use disorders, environmental influences on the expression of liability, comorbid disruptive behavior problems, and temperament and personality, particularly behavioral disinhibition. |
| Naimah Weinberg, M.D. | Gene by environment by development interplay in the etiology and trajectories of substance use disorders and comorbid psychiatric conditions, and related methodologic studies. |
Division of Pharmacotherapies and Medical Consequences of Abused Drugs (DPMCDA)
| Name | Interests |
|---|---|
| Jag H. Khalsa, Ph.D. | Genetics of metabolic (including nutritional) & endocrine disorders of drug abuse, co-occurring infections (HIV, hepatitis C, TB, STDs); genetics of drug-drug interactions among antiretrovirals, drugs of abuse and addiction treatment medications. |
| Iván D. Montoya, M.D., M.P.H. | Pharmacogenetics of the safety and efficacy of medications approved or being investigated for the treatment of substance use disorders. |
| Amrat P. Patel, Ph.D. | Medication development, neurotransmitter transporter pharmacology, pharmacokinetics, and metabolism. |
Intramural Research Program
| Name | Interests |
|---|---|
| George Uhl, M.D. Ph.D. | Genetics and molecular neurobiology of addictions; association genome scanning; pooled association genome scanning. |
NIDA Clinical Trials Network
| Name | Interests |
|---|---|
| Raul Mandler, M.D. | Pharmacotherapy clinical investigation and translational medicine |
NIDA Office of AIDS Research Program
| Name | Interests |
|---|---|
| Diane M. Lawrence, Ph.D. | HIV/AIDS, neuropathogenesis, inflammation, neuroimmunology, neuron-glia interactions. |
Office of Extramural Affairs
| Name | Interests |
|---|---|
| Mark R. Green, Ph.D. | Peer/grant review. |
| Meenaxi Hiremath, Ph.D. | Grants receipt and referral. |
| Mark Swieter, Ph.D. | Training and career development and peer/grant review. |
Attention
Due to the lapse in government funding, the information on this web site may not be up to date, transactions submitted via the web site may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. Updates regarding government operating status and resumption of normal operations can be found at
Looking for Treatment?
Use the SAMHSA Treatment Locator or 1-800-662-HELP.
Helpline open during government shutdown
Featured Publication
2010 Strategic Plan
Outlines NIDA’s drug abuse and addiction research strategic priorities for the next 5 years, focusing on prevention, treatment, HIV/AIDS, and other cross-cutting issues.